Intellogic

The main activity of the company is the development of systems for recognizing diagnostic medical images, diagnosing and assessing the risks of developing diseases based on artificial intelligence technologies.

Product

For 2019, the company's main product is Botkin.AI (formerly TeleMD), a software platform that uses artificial intelligence technologies to diagnose and assess the risks of developing cancer by analyzing medical images and other patient data. The program will also allow the doctor to contact the medical community for remote consultations.

The project team is formed from specialists in the field of neural networks and artificial intelligence, as well as scientific medical advisers in the field of oncology and radiology. Botkin.AI diagnostic criteria and algorithms are developed in cooperation with the N.N. Blokhin Russian Cancer Research Center and other scientific and clinical centers.

The use of artificial intelligence is one of the most promising trends in medicine. Activity in this market is demonstrated by Amazon, Apple, Google, IBM, Medtronic, Microsoft, Propeller Health and other corporations that are interested in both financing their own developments and buying ready-made solutions.

2020: Attracting 160 million rubles of investment

The company "Intellojik," a resident of the Cluster of Biomedical Technologies of the Skolkovo Foundation, attracted 160 million rubles of investment in round B in order to further develop the artificial intelligence platform for the analysis of medical research Botkin.AI. This was announced by the Skolkovo Foundation on December 23, 2020.

The lead investor was the company. Unicorn Capital Partners It manages the FarmMed Innovation Venture Fund, which focuses on investments in drug development medical devices software , and for use in. to medicine The co-investor of the round was Tashir MEDICA, an investment holding specializing in financing and strategic development of assets in the field. The health care round also involved all current investors of Intellojik - venture funds, (UK RBV Capital Digital Evolution Ventures Orbit Capital Partners), PrimerCapital and ExpoCapital.

The Botkin.AI platform is designed to analyze and determine pathologies in diagnostic studies of computed tomography, X-ray, mammography. The project uses its own patented technology for creating mathematical models of patients based on artificial intelligence. The platform is already commercially used by radiologists in a number of regions of Russia and in pilot projects abroad.

The current round of investments is aimed at further developing and ensuring the scaling of the platform, expanding sales in Russia and entering international markets.

Sergey Sorokin, CEO of Intellojik, founder of the Botkin.AI project: {{quote 'Our project is reaching a different level of development. Our technologies allow us to develop our platform as a comprehensive product of a fundamentally different class for the medical research analysis market. These investments and shareholders will help us not only strengthen our position in the Russian market, but also become a noticeable player in the international arena. }}

The coronavirus pandemic spurred an already high interest in artificial intelligence technologies in medicine, opening up a number of opportunities for the commercial introduction of the Botkin AI platform into medical practice. The company "Intellojik" combines a professional team, world-class development and a first-class syndicate of investors, which makes it an attractive object for investment.

We highly appreciate the potential of using artificial intelligence in medicine and especially in functional diagnostics. The Botkin.AI solution has excellent prospects for scaling in local and international markets.

Arkady Dvorkovich, Chairman of the Skolkovo Foundation: {{quote 'Since 2017, we have consistently supported the Botkin.AI project at every stage of development, from development to implementation. Thanks to the use of artificial intelligence technologies, Botkin.AI makes the recognition of diagnostic images of computed tomography and diagnosis more effective and accessible and allows radiologists to detect thousands of cases of the disease in the early stages. The project proved to be excellent in a difficult pandemic period due to the reduction of the burden on doctors, when the speed and high accuracy of detecting pathologies acquired particular importance. It is such decisions that save lives, allow people to live for many, many more years, and are supported by the Skolkovo Foundation. We are confident that with this round of investments and the addition of additional shareholders, the Botkin.AI project will realize its innovative potential and take a worthy place among the solutions of the new generation for healthcare. }}

The Botkin.AI platform received a registration certificate as a medical product with risk class 2b artificial intelligence technology. The use of artificial intelligence certainly expands the capabilities of the Russian medical industry, especially in the field of functional diagnostics, including the diagnosis of diseases with great health risks, such as cancer, as well as for screening.

Valentin Sinitsyn, Professor, President of the Russian Society of Radiologists and Radiologists, Head of the Radiation Diagnostics Course of the Faculty of Fundamental Medicine of Moscow State University: {{quote 'Artificial Intelligence for the Analysis of Diagnostic Images - the most discussed topic in radiation diagnostics over the past 5 years. The experience of our cooperation with Intellojik shows that its management and employees have correctly chosen strategic goals for the development and implementation of its products. We use the Botkin.AI platform for both scientific and practical purposes. I am glad that the domestic company works at such a high level, achieves its goals, is growing dynamically and has ambitious plans for the near future. }}

2019: Raising 100 million rubles from a group of investors

The company "Intellojik," developing the project, Botkin.AI attracted 100 million rubles. from the funds of Digital Evolution Ventures (created with the participation of Rosatom"") and (RBV Capital founded by "" R-Pharm Alexei Repik and), Russian Venture Capital Company as well as current investors - and " Primer Capital ExpoCapital." The closing of the round on May 29, 2019 was announced with Kommersant reference to a representative of Orbita Capital (managing company Digital Evolution Ventures). This information was confirmed to the publication by other investors.

Botkin.AI develops a system based on artificial intelligence (AI) to analyze and determine pathologies in CT scans, X-rays and mammograms. The company says that they have already implemented pilot projects for the early diagnosis of lung cancer in four regions of Russia.

Botkin.AI determines pathologies in CT and X-ray images

The company intends to direct new investments to research and development in the field of AI for, health care product certification and entry into foreign markets. First of all, Southeast markets are considered, Asia then - and, Europe USA said the founder of Botkin.AI. Sergey Sorokin

According to Orbita Capital, the market for AI-based healthcare products in the world is growing by more than 40% per year and will reach $150 billion by 2026. Similar technologies for diagnosing diseases are being developed by Google, IBM and the Israeli Zebra Medical Vision, launched in 2014 and attracting, according to Crunchbase, about $20 million in investments.

Scientists began to develop the use of AI to search for pathologies back in the 2000s. However, before the widespread use of such developments in domestic medicine, several more years may pass, given the conservative nature of healthcare in Russia, says Alexey Grinenko, investment manager of the Internet Initiatives Development Fund. At the same time, Botkin.AI technology can have wide prospects in the global market. If the company decides to fully develop business in other regions, it will most likely need another round of investments, the expert believes.

Despite the fact that entering developed markets is more difficult and more expensive, the possibilities for introducing the product are much wider. This is due to the specifics of the legislation and the readiness of the medical community to introduce new products, "Grinenko explains.

The use of AI for diagnostics in the field of cancer is a topic that dozens, if not hundreds of companies around the world, are working on, but it is still difficult to say who will be able to create the product in demand, said Alexey Solovyov, partner at iTech Caption In his opinion, for such a complex product and b2b sales model, investments of 100 million rubles. insufficient.

The company will need to demonstrate the development of the product and begin sales abroad in order to raise funds in the next rounds in international markets, he said.

The exit of current investors from Botkin.AI is possible only in favor of a strategic foreign player, suggests Solovyov, noting that the company is working closely, for example, with the pharmaceutical giant Bayer.

2017: Primer Capital invested 11 million rubles in the project TeleMD

In the summer of 2017, it became known that the venture biotech fund Primer Capital invested 11 million rubles in the TeleMD project. Primer Capital was the sole investor in the round.

"Existing methods for diagnosing medical images are not automated and subjective, and the share of medical error in visual diagnosis by qualified specialists exceeds 30%," says Teplukhina Ekaterina, CEO of Primer Capital, "More than half of clinics in the United States plan to use artificial intelligence technologies in the next 5 years. A significant part of this market will be image analysis systems. Primer Capital is glad to support the Russian project of such great potential. "

"The platform TeleMD includes unique technologies that combine the use of artificial intelligence and medical knowledge. These technologies can be used to diagnose, predict the development of diseases, as well as for clinical research. This round of investments will allow us to complete the creation of functionality for image recognition in the diagnosis of cancer. The next step will be scaling the project with the ability to analyze heterogeneous medical data for different nosologies. In fact, we are creating a new generation product - AI-as-a-Service for healthcare, "comments project manager TeleMD Sorokin Sergey, CEO of Intellojik. TeleMD will be presented both as a cloud solution and as a standalone software product.

See also

• Artificial Intelligence in Medicine